Business Wire

Der hier verfügbare Newsfeed wird von unserem Content-Partner Business Wire bereitgestellt. Es handelt sich dabei um einen der bedeutendsten und reichweitenstärksten Pressedienste, die Nachrichten, Pressemitteilungen und Multimedia-Inhalte an Medien, Journalisten und der Öffentlichkeit zur Verfügung stellen. Business Wire ist ein Tochterunternehmen des Warren-Buffett-Konzerns Berkshire Hathaway.
Der NewsWire-Hub ("X-Billboard") umfasst derzeit vfünf der wichtigsten internationalen Nachrichtenquellen und wird durch einen Börseninformationsservice ergänzt. Die einzelnen Newswire-Services ergänzen sich und bilden ein komplementäres Informationsangebot, mehr als drei Viertel der offiziellen Nachrichtenquellen ab, auf die sich Redaktionen weltweit bei ihrer Börsenberichterstattung stützen. Ihr Vorteil: Sie finden hier alles in einer Übersicht. Über die Steuerelemente können Sie zu den einzelnen Bereichen navigieren. Im Terminalview können Sie gezielt auf Unternehmensebene individuelle Recherchen durchführen.
presented by
H
More Tools & Gadgets
Systemstatus: 35.500 Nachrichten wurden bislang erfolgreich verarbeitet
EXCHANGE NEWSBOARD
                              
NEWSWIRE INFOBOARD
                              
Business Wire ist eine wichtige Nachrichtenquelle, die über das X-Billboard abgerufen werden kann. Sie ist Teil des Newswire-Hub, der für Börsianer wichtige internationalen Nachrichtenquellen an einem zentralen Ort bündelt. Wer sich schnell einen Überblick verschaffen will, kann sich bequem durch die Headlines scrollen. Wer sich detailliert mit den Nachrichten auseinandersetzen möchte, kann über die Detailansichten der Info-Cards direkt auf die jeweilige Nachricht und weitere Analysewerkzeuge zugreifen.
NEWS
EXPLORER
US30052C1071
Letzte Aktualisierung: 01.04.2025 | 6PM
Kennen Sie bereits den neuen Terminal-View? Folgen Sie bei Interesse dem folgenden Link.
FIGI: BBG005CX4HK8
EOLS
Evolus, Inc.
GICS: - · Sektor: Healthcare · Sub-Sektor: Drug Manufacturers—Specialty & Generic
NAME
Evolus, Inc.
ISIN
US30052C1071
TICKER
EOLS
MIC
XNAS
REUTERS
EOLS.OQ
BLOOMBERG
EOLS US
Di., 25.03.2025       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in a fireside chat and investor meetings at the upcoming Needham Annual Virtual Healthcare Conference. The fireside chat will take place on Tuesday, April 8, 2025, at 12:45...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Fr., 21.03.2025       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of 29,763 restricted stock units (RSUs) of the company’s common stock to 14 newly hired non-executive employees of the company. The awards were approved by the compensation committee of the company’...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Di., 04.03.2025       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced its financial results for the fourth quarter and full-year ended December 31, 2024. “We reached a significant inflection point in 2024, achieving full-year profitability1 ahead of expectations while delivering our fifth conse...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Do., 27.02.2025       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in fireside chats and investor meetings at upcoming investor conferences in Miami, FL: The Leerink Partners Global Biopharma Conference, the fireside chat will take place...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Do., 20.02.2025       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will participate in the TD Cowen 2nd Annual Glowing Ahead: Beauty & Wellness Summit in New York City on Thursday, February 27, 2025. As part of the event, David Moatazedi, President and...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Di., 18.02.2025       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its fourth quarter and year end 2024 financial results on Tuesday, March 4, 2025, after the U.S. financial markets close. Evolus management will host a conference call and live webcast t...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Do., 13.02.2025       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that the U.S. Food and Drug Administration (FDA) has approved Evolysse™ Form and Evolysse™ Smooth injectable hyaluronic acid (HA) gels, the first two products in the Evolysse™ collection. These approvals mark Evolus’ entry int...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Sa., 08.02.2025       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 26,897 shares of Evolus and an aggregate of 99,826 restricted stock units (RSUs) of the company’s common stock to 34 newly hired non-execut...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Di., 21.01.2025       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a global performance beauty company with a focus on building an aesthetic portfolio, today announced its preliminary, unaudited net revenue for the fourth quarter and full-year ended December 31, 2024. The preliminary unaudited results described in this press release are based on the most current information available ...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Fr., 17.01.2025       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in January of an aggregate of 15,332 restricted stock units (RSUs) of the company’s common stock to 6 newly hired non-executive employees of the company. The awards were approved by the compensation...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Fr., 13.12.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November non-qualified stock options to purchase an aggregate of 9,872 shares of Evolus and an aggregate of 16,596 restricted stock units (RSUs) of the company’s common stock to 9 newly hired non...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Mi., 06.11.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported financial results for the third quarter ended September 30, 2024, and provided a business update. “Our third quarter results underscore the momentum we’ve been building throughout the year,” said David Moata...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Fr., 01.11.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced that members of its management team will present at the Stifel Healthcare Conference in New York City on Tuesday, November 19 at 10:55 AM ET. The presentation can be accessed on the Investor Relations page of the Evolus websi...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Do., 31.10.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the EU Medical Device Regulation (MDR) certification was received for four unique injectable hyaluronic acid (HA) gels under the brand name Estyme® (pronounced “esteem”), branded as Evolysse™ in the U.S. mar...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Di., 29.10.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced it recently surpassed one million enrolled consumers and completed the two-millionth Jeuveau® redemption in its Evolus Rewards™ patient loyalty program. “The achievement of these milestones underscores the ...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Mi., 23.10.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced that it will report its third quarter 2024 financial results on Wednesday, November 6, 2024, after the U.S. financial markets close. Evolus management will host a conference call and live webcast to discuss...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Sa., 12.10.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of non-qualified stock options to purchase an aggregate of 10,251 shares of Evolus and an aggregate of 31,049 restricted stock units (RSUs) of the company’s common stock to 16 newly hired non-execut...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Sa., 28.09.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant of an aggregate of 10,845 restricted stock units (RSUs) of the company’s common stock to 5 newly hired non-executive employees of the company. The awards were approved by the compensation committee ...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Fr., 06.09.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio, today announced the company will be ringing the Nasdaq closing bell on Friday, September 13, 2024. The Nasdaq closing bell ceremony is a time-honored tradition, serving as a platform for companies to celebrate achievements and milestones. T...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink
Fr., 09.08.2024       Evolus
US30052C1071

Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in July an aggregate of 46,363 restricted stock units (RSUs) of the company’s common stock to 16 newly hired non-executive employees of the company (the “July Grants”). The Company also is reporting...
weiterlesen
Evolus
Research & Analysen Termsheet Terminal
Permalink

Die hier zur Verfügung gestellten Informationen unterliegen keiner redaktionellen Bearbeitung. Die Aufbereitung erfolgt vollautomatisch und wird durch Zusatzinformationen und weiterführende Recherchemöglichkeiten angereichert. Ziel der Inhalte ist die schnelle und unkomplizierte Versorgung der Informationssuchenden mit den für sie relevanten Informationen. Durch eine Rückverlinkung auf den Informationsanbieter und -eigentümer ist sichergestellt, dass die hier aufbereiteten Daten bei Bedarf mit den Quellinformationen abgeglichen werden können. Das Newsboard zeigt keine Informationen in Echtzeit. Diese bitten wir bei Bedarf beim Börsenbetreiber abzurufen. Es besteht kein Anspruch auf Vollständigkeit. Hochverfügbarkeit kann nicht gewährleistet werden. Sollten Sie Fehler in der Funktionsweise bemerken, teilen Sie uns diese über das weiter unten befindliche Formular "Report a Bug" mit.

RAW DATA PROCESSING bedeutet, dass Rohdaten verarbeitet werden, ohne den Inhalt zu verändern. Um die Interpretation der Information im Sinne der Nutzbarkeit zu verbessern, werden die Daten ergänzt. 

Hinweis: Über das Newswire-Crosslink-Panel im oberen Bereich gelangen Sie schnell und bequem zu weiteren Informationsquellen. Im Terminalview sind die Nachrichten auf Unternehmensebene gefiltert und ermöglich darüber gezielte Recherchen.

Wir bedanken uns im Namen der Investoren-Community bei BusinessWire für die Bereitstellung der News- und Datenfeeds